Summit on Challenges and Solutions in Quality & Safety of Homeopathic Drug Products

June 27-28, 2019 | Hilton Baltimore Inner Harbor

Safety Track: Workshop 3
3:00–4:30 p.m.

Populations and Routes of Administration
Presented by Matthew D. Reed, PhD, DABT, Fellow ATS, Principal, Coelus LLC

About the Presenter
With more than 25 years of experience in pharmacology, toxicology, and nonclinical development, Matt Reed is the Principal and CEO of Coelus LLC where he facilitates early to late phase development of pharmaceutical IP and provides consulting services in integrated drug development strategies, toxicology, pharmacology, and hazard assessment. Dr. Reed is a pharmacologist, board certified toxicologist, ABT Board Member, and Fellow of the Academy of Toxicology Sciences (ATS). He has been a part of multiple successful R&D programs that that have transitioned to IND, NDA and other regulatory registration milestones for small molecules, biologics, oligonucleotides, and alternative fuel additives.

Dr. Reed has developed large scale hazard assessment programs, Integrated Drug Development Plans and timelines, and has developed hundreds of safety and pharmacology programs for R&D initiatives. Specifically, he has overseen and consulted on initiatives to include toxicant/ drug delivery, applied toxicology studies, formulation/device feasibility and development, pharmacokinetics, pharmacology, safety pharmacology, pivotal IND and NDA GLP compliant studies, etc. Dr. Reed has been an awardee, PI/ Co-PI, or subcontract PI of over $51M in federal R&D grants and contracts for drugs and vaccines (delivery by multiple routes) working with government funded commercial firms, NIH, BARDA and DOD to develop pharmaceutics for clinical indications as well as combat, homeland, and defense security threats.